VivoSeq
Oncology

Hepatocellular Carcinoma

630

Pipeline Programs↗

315

Active Trials↗

165

Companies Involved↗

Hepatocellular Carcinoma is a highly competitive landscape with 630 programs across 165 companies. The most active players are Incyte, Lee's Pharmaceutical Limited, Wondercel Biotech (ShenZhen). 47 therapies are approved with 111 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

100/100

Pipeline Velocity

83/100

Mech. Concentration

4/100

Completion Rate

70/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Incyte logo

Incyte

3 programs

Phase 1L

Lee's Pharmaceutical Limited

2 programs

Phase 1W

Wondercel Biotech (ShenZhen)

2 programs

Phase 1A

AVEO Pharmaceuticals, Inc.

1 program

Phase 1C

Captor Therapeutics S.A.

1 program

Phase 1O

Oncozyme Pharma Inc.

1 program

Phase 1

Pipeline

Programs by Phase

Preclinical75

Alcohol

Astellas

Adefovir Dipivoxil

Gilead

Palbociclib

Pfizer

PD-1

Sichuan Baili Pharmaceutical Co., Ltd.

Anti-PD-1 Monoclonal Antibody

iTeos Therapeutics

Phase 1105

Mitoxantrone Hydrochloride

Pfizer

Itacitinib

Incyte

Celecoxib

Philadelphia Eye Associates

Ganetespib

Synta Pharmaceuticals Corp.

Artesunate

Amivas Inc.

Phase 2292

Veliparib

AbbVie

Baclofen

Novartis

Ivonescimab

Summit Therapeutics

Pravastatin

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Enzalutamide

Astellas

Phase 3111

Epirubicin Hydrochloride

Merck & Co.

Regorafenib

Bayer

Serplulimab

Shanghai Henlius Biotech

Osimertinib

AstraZeneca

Toripalimab

Coherus Oncology, Inc.

Approved47

Deferoxamine

Alnylam Pharmaceuticals

Entecavir

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Floxuridine

Pfizer

Alectinib

Roche

Polyethylene Glycol

Bayer

Analysis

Modality Breakdown

86%

Small molecule

618 of 719 classified programs — the dominant modality here.

14%ALL OTHERSMonoclonal antibody639%Cell therapy213%Vaccine91%Peptide3<1%Radiopharmaceutical3<1%Protein / enzyme1<1%Other1<1%

Small molecule leads; the ring shows all 719 classified programs, each share of the total. Modality classified for 99% of 798 pipeline programs.

Analysis

Trial Status

1,046

clinical trials

Completed326 · 31%
Unknown status266 · 25%
Recruiting171 · 16%
Terminated96 · 9%
Not yet recruiting90 · 9%
Active, not recruiting53 · 5%
Other44 · 4%

Clinical Trials

Trial Activity

1046 trials

Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.
Recruiting·SSecond Affiliated Hospital of Guangzhou Medical University·Phase 2·NCT06492408·90 enrolled
Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis
Recruiting·CCan-Fite BioPharma·Phase 3·NCT05201404·471 enrolled
A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 in Combination With Valganciclovir (VGCV) and Atezolizumab/Bevacizumab in Subjects With Hepatocellular Carcinoma
Recruiting·RRznomics, Inc.·Phase 1/2·NCT06695026·45 enrolled
Autologous Neoantigen-Specific T-Cell Therapy for Advanced Hepatocellular Carcinoma
Recruiting·ZZhejiang University·Phase 1/2·NCT07123545·20 enrolled
A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/Recurrent Hepatocellular Carcinoma (HCC)
Recruiting·SShanghai AbelZeta Ltd.·Phase 1/2·NCT06590246·121 enrolled
A Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular Carcinoma
Recruiting·WWest China Hospital·Phase 1/2·NCT07482059·33 enrolled
Single Centre Prospective Evaluation of 68Gallium-FAPI PET/MRI in Hepatocellular Carcinoma
Recruiting·NNational University Hospital, Singapore·Phase 1·NCT05687747·100 enrolled
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
Recruiting·EEmory University·Phase 2·NCT05103904·19 enrolled
Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma
Recruiting·TThe First Affiliated Hospital of Xiamen University·Phase 2·NCT05970666·71 enrolled
CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection
Recruiting·CCARsgen Therapeutics Co., Ltd.·Phase 1·NCT06560827·30 enrolled
Mts105 for Advanced Hepatocellular Carcinoma
Recruiting·—·Phase 1·NCT06689540·14 enrolled
SBRT Plus Systemic Therapy vs Systemic Therapy Alone in BCLC C Hepatocellular Carcinoma
Recruiting·SShandong Cancer Hospital and Institute·Phase 2·NCT07274774·184 enrolled
mFOLFOX7 Plus Camrelizumab and Apatinib in BCLC Stage A/B Hepatocellular Carcinoma Patients Beyond Milan Criteria
Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT06607107·29 enrolled
Phase IIb Study of AST-3424 in Patients With AKR1C3-high Expressing Advanced Hepatocellular Carcinoma
Recruiting·ZZhejiang Hisun Pharmaceutical Co. Ltd.·Phase 2·NCT07310173·75 enrolled
Palliative Hepatectomy Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma
Recruiting·—·Phase 1·NCT06470256·50 enrolled
Page 1 of 70

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)